pagibaximab

INTRODUCTION Advances in modern medicine have given very low birth weight (VLBW) infants a better chance of survival; however… (More)

BACKGROUND Pagibaximab, a human chimeric monoclonal antibody developed against lipoteichoic acid, was effective against… (More)

This overview of 25 monoclonal antibody (mAb) and 5 Fc fusion protein therapeutics provides brief descriptions of the candidates… (More)

Sepsis-related morbidity and mortality are major problems in NICU. Preterm neonates display clinical characteristics that make… (More)

Staphylococcal sepsis is a major cause of morbidity and mortality in very-low-birth-weight (VLBW) infants. A human chimeric… (More)

A chimerized (murine/human) monoclonal antibody (pagibaximab) against lipoteichoic acid (LTA) and protective in animal models for… (More)